Pharmaceutical giant AstraZeneca writes $440m cheque for UCL spin-out Spirogen.

Spirogen, a life sciences spin-out of University College London, has been acquired by pharmaceutical conglomerate AstraZeneca for $440m.

The trade sale, made through AZ subsidiary MedImmune, will see AstraZeneca pay $200m up front in cash with a further $240m in return for the firm achieving developmental milestones.

Spirogen is developing cancer-fighting technology known as proprietary pyrrolobenzodiazepine. The process essentially designates tumours with biodegradable linkers which then attract cytoxic agents, colloquially known as warheads, to the site. This provides direct delivery…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?